Generics Ask HHS To Include Rebate, Biosimilar Policies In Plan To Biden

By John Wilkerson / August 20, 2021 at 4:50 PM
Proposals to avoid rebate walls, mandate preferred formulary placement for biosimilars and share savings from biosimilars with doctors are among the many policies that the generic drug industry suggests HHS include in a drug-pricing report due to President Biden Monday (Aug. 23). The Association for Accessible Medicines also would like HHS to clarify rules for so-called skinny labels because the generic drug lobby says a recent court ruling makes the common tactic all but impossible for generic drug makers to...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.